Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro), are medications used to treat type 2 diabetes and obesity.
October 10, 2025
high
temporal
Baseline description of the drug class and common brand examples.
Use of GLP-1 receptor agonists can produce atypical tracer uptake on PET and CT scans that may mimic disease and therefore has the potential to lead to additional diagnostic tests, incorrect cancer assessments, or delays in treatment.
October 10, 2025
high
temporal
Clinical implication of altered imaging patterns associated with metabolic-effecting medications.
GLP-1 receptor agonist medications (examples include semaglutide, liraglutide, and tirzepatide) mimic endogenous hormones that help regulate blood sugar and appetite.
high
general
Pharmacologic description of the GLP-1 receptor agonist drug class.
GLP-1 receptor agonists delay gastric emptying, which slows the rate at which orally consumed alcohol is absorbed from the gut into the bloodstream.
high
general
Mechanism by which GLP-1 medications can alter the pharmacokinetics of orally ingested substances such as alcohol.
Many medications used to treat obesity and Type 2 diabetes are administered by injection.
high
medical
Several commonly used GLP-1 receptor agonists and similar therapies are injectable formulations.